ArticleDiscover oncology2025
SLC3A2 as a key anoikis-related gene for prognosis and tumor microenvironment remodeling in melanoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acid stress modulates metabolo-inflammatory pathways in oral epithelial cells.bioRxiv : the preprint server for biology · 2026Article
- Single-cell landscape of melanoma reveals ETV5-driven C3 ID4Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAnoikis, a form of programmed cell death triggered by detachment from the extracellular matrix, plays a crucial role in metastasis and immune escape in melanoma. We aimed to identify anoikis-related prognostic markers using integrated machine learning and single-cell analysis.
methodsWe integrated single-cell RNA sequencing data from the GEO dataset GSE215120 and transcriptomic profiles from multiple melanoma cohorts, including TCGA, GSE19234, GSE22153, and GSE65904. Batch effects in single-cell data were corrected using the Harmony algorithm. Cell subpopulations were annotated via t-SNE dimensionality reduction and canonical markers, and AUCell was employed to compute the enrichment scores of anoikis-related genes across cell subtypes. A total of 150 anoikis-related genes were identified, and 101 machine learning algorithms and their combinations (including Cox regression, random survival forest, and gradient boosting machine) were systematically evaluated to identify the optimal prognostic model. Model performance was validated in independent cohorts using the concordance index (C-index), Kaplan-Meier survival analysis, and time-dependent ROC curves. Tumor microenvironment characteristics were assessed using ESTIMATE, CIBERSORT, and GSVA. The clinical relevance and functional role of SLC3A2 were further validated using the BEST database and in vitro experiments, including shRNA-mediated knockdown, colony formation, and Transwell migration assays.
resultsSingle-cell analysis revealed significantly elevated anoikis scores in endothelial cells, fibroblasts, and melanocytes. High-scoring subpopulations exhibited more active cell-cell communication networks centered on endothelial cells. The "random survival forest + gradient boosting machine" model demonstrated optimal prognostic performance across the TCGA training cohort and validation cohorts (GSE19234, GSE22153, GSE65904), with a C-index of 0.774. Patients in the high-risk group had significantly shorter overall survival, and the model achieved strong predictive accuracy with AUCs ranging from 0.64 to 0.81 for 1-, 3-, and 5-year survival. Tumor microenvironment analysis indicated reduced immune infiltration (CD8⁺ T cells, B cells) in the high-risk group, suggestive of an immunosuppressive phenotype. SLC3A2 was highly expressed in melanoma and correlated with advanced T stage, drug resistance, and poor prognosis. Knockdown of SLC3A2 suppressed melanoma cell proliferation and migration in vitro.
conclusionThis study highlights the pivotal role of anoikis resistance in melanoma heterogeneity and immune microenvironment remodeling. The machine learning-based prognostic model we constructed holds clinical translational potential, and SLC3A2 was validated as a potential therapeutic target, offering new strategies for precision treatment of melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.